Results of Some of the Main Alternating or Hybrid Multiple-Drug CT Regimens in the Treatment of Advanced HD
| Study . | Treatment . | No. of Patients . | CR (%) . | OS . | RFS . | FFS . | Follow-Up (median, mo) . |
|---|---|---|---|---|---|---|---|
| Canellos et al17 | MOPP (no RT) | 123 | 67 | 66 | — | 50 | 60 |
| ABVD (no RT) | 115 | 82 | 73 | — | 61 | 60 | |
| MOPP/ABVD alt. (no RT) | 123 | 83 | 75 | — | 65 | 60 | |
| Hancock et al15 | LOPP + IF RT | 295 | 57 | 66 | 52 | — | 60 |
| LOPP/EVAP alt. + IF RT | 299 | 64 | 75 | 72 | — | 60 | |
| Cullen et al16 | ChlVPP/PABIOE + IF RT | 216 | 85 | 78 | — | 68 | 60 |
| Radford et al20 * | MVPP + IF RT | 208 | 58 | 71 | — | (PFS: 66) | 54 |
| ChlVPP/EVA hybr. + IF RT | 211 | 72 | 80 | — | (PFS: 80) | 54 | |
| Bartlett et al41 | MDVPVBE (Stanford V) (+IF RT) | 65 | — | 96 | — | 87 | 24 |
| Viviani et al19 | MOPP/ABVD alt. + IF RT | 211 | 91 | 74 | 74 | 67 | 108 |
| MOPP/ABVD hybr. + IF RT | 204 | 89 | 72 | 76 | 69 | 108 | |
| Diehl et al21 | BEACOPP + IF RT | 30 | 93 | 96 | 96 | 89 | 40 |
| Martinelli et al40 | ChlVPP/ABVVp16 | 28 | 95 | 75 | — | 70 | 48 |
| This series | MOPPEBVCAD (+IF RT) | 145 | 94 | 86 | 82 | 78 | 66 |
| Study . | Treatment . | No. of Patients . | CR (%) . | OS . | RFS . | FFS . | Follow-Up (median, mo) . |
|---|---|---|---|---|---|---|---|
| Canellos et al17 | MOPP (no RT) | 123 | 67 | 66 | — | 50 | 60 |
| ABVD (no RT) | 115 | 82 | 73 | — | 61 | 60 | |
| MOPP/ABVD alt. (no RT) | 123 | 83 | 75 | — | 65 | 60 | |
| Hancock et al15 | LOPP + IF RT | 295 | 57 | 66 | 52 | — | 60 |
| LOPP/EVAP alt. + IF RT | 299 | 64 | 75 | 72 | — | 60 | |
| Cullen et al16 | ChlVPP/PABIOE + IF RT | 216 | 85 | 78 | — | 68 | 60 |
| Radford et al20 * | MVPP + IF RT | 208 | 58 | 71 | — | (PFS: 66) | 54 |
| ChlVPP/EVA hybr. + IF RT | 211 | 72 | 80 | — | (PFS: 80) | 54 | |
| Bartlett et al41 | MDVPVBE (Stanford V) (+IF RT) | 65 | — | 96 | — | 87 | 24 |
| Viviani et al19 | MOPP/ABVD alt. + IF RT | 211 | 91 | 74 | 74 | 67 | 108 |
| MOPP/ABVD hybr. + IF RT | 204 | 89 | 72 | 76 | 69 | 108 | |
| Diehl et al21 | BEACOPP + IF RT | 30 | 93 | 96 | 96 | 89 | 40 |
| Martinelli et al40 | ChlVPP/ABVVp16 | 28 | 95 | 75 | — | 70 | 48 |
| This series | MOPPEBVCAD (+IF RT) | 145 | 94 | 86 | 82 | 78 | 66 |
*Fifteen percent of the patients with stage IB-IIA.